

=== SOURCE: primary.html ===

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 26, 2023 ( July 21, 2023 )
Alnylam Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-36407
77-0602661
(State or other jurisdiction of incorporation)
(CommissionFile Number)
(I.R.S. Employer Identification No.)
(State or other jurisdiction
of incorporation)
(I.R.S. Employer
Identification No.)
675 West Kendall Street ,		
Henri A. Termeer Square		
Cambridge , Massachusetts		02142
(Address of principal executive offices)		(Zip Code)
Registrant’s telephone number, including area code: (617)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (General Instruction A.2. below):
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Soliciting material pursuant to Rule under the Exchange Act (17 CFR
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
communications pursuant to Rule under the Exchange Act (17 CFR
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
communications pursuant to Rule under the Exchange Act (17 CFR
Securities registered pursuant to Section 12(b) of the Act:
Title of each class		TradingSymbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value per share		ALNY		The Nasdaq Stock Market LLC
Title of each class
TradingSymbol(s)
Name of each exchange
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule of the Securities Exchange Act of 1934 of this chapter).
☐	Emerging Growth Company
Emerging Growth Company
☐	If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01	Entry into a Material Definitive Agreement.

=== Item 1.01 ===

Entry into a Material Definitive Agreement.
On July 21, 2023 (the “”), Alnylam Pharmaceuticals, Inc. (the “”), entered into a Collabor